Platelet Inhibition With CANgrelor and Crushed TICagrelor in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: The CANTIC Study

Trial Profile

Platelet Inhibition With CANgrelor and Crushed TICagrelor in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: The CANTIC Study

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Cangrelor (Primary)
  • Indications Myocardial infarction
  • Focus Pharmacodynamics
  • Acronyms CANTIC
  • Most Recent Events

    • 24 Oct 2017 Planned End Date changed from 1 Dec 2018 to 1 Feb 2019.
    • 24 Oct 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2018.
    • 24 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top